ESMO 2026 abstracts featuring FCS research:

ESMO 2026 展示 FCS 研究的摘要：

52P,

52P，

1017P, 1076TiP, 1021P, 1134eTiP, 1146eTiP, 1594P, 1846P, 3151P, 2216O

1017P，1076TiP，1021P，1134eTiP，1146eTiP，1594P，1846P，3151P，2216O

FORT MYERS, Fla.

佛罗里达州，迈尔斯堡

,

，

Oct. 23, 2026

2026年10月23日

/PRNewswire/ -- Findings from early-phase clinical research conducted with participation from

/美通社/ -- 在参与下开展的早期阶段临床研究的发现

Florida Cancer Specialists & Research Institute, LLC

佛罗里达癌症专家与研究所有限责任公司

(FCS) will be showcased this week at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid. FCS physician leaders in drug development are first authors on studies selected for presentation at the prestigious international meeting.

(FCS) 将在本周于马德里举行的2026年欧洲肿瘤内科学会（ESMO）大会上展示。FCS在药物研发领域的医师领导者是入选在该享有盛誉的国际会议上发表的研究的第一作者。

Continue Reading

继续阅读

FCS research leaders will present early-phase clinical trial findings at ESMO Congress 2026, advancing innovative cancer treatments.

FCS研究负责人将在2026年欧洲肿瘤内科学会（ESMO）大会上展示早期临床试验结果，推动创新癌症治疗的发展。

Recognized as one of the world's premier oncology conferences, the ESMO Congress convenes leading cancer researchers, clinicians and industry experts to present cutting-edge science and explore advances shaping the future of cancer care.

ESMO 大会被公认为全球顶级的肿瘤学会议之一，汇聚了领先的癌症研究人员、临床医生和行业专家，旨在展示前沿科学成果，并探讨塑造癌症诊疗未来的最新进展。

'Many of the targeted therapies now transforming cancer care first entered clinical testing through Phase 1 trials at our drug development units,' said FCS Director of Drug Development

“许多目前正在改变癌症治疗格局的靶向疗法，最初都是通过我们药物研发部门的Ⅰ期临床试验进入临床测试阶段的。”FCS药物研发总监表示。

Manish R. Patel, MD

马尼什·R·帕特尔，医学博士

, who oversees early-phase research at the FCS drug development units in Sarasota and Lake Nona. 'FCS is proud to help drive scientific discoveries that expand treatment options, create new possibilities and improve outcomes for patients everywhere.'

，负责监督FCS在萨拉索塔和莱克诺纳的药物研发部门的早期阶段研究。“FCS自豪地助力推动科学发现，以拓展治疗选择、创造新的可能性并改善全球患者的治疗结果。”

The following abstracts feature an FCS first author and will be shared in poster presentations at the ESMO Congress:

以下摘要的第一作者来自FCS，并将在ESMO大会上以海报形式展示：

Cesar Perez, MD

塞萨尔·佩雷斯，医学博士

, director of the Drug Development Unit at the Sarah Cannon Research Institute at FCS is first author of the study, 'A first-in-human phase 1/2 dose-escalation and expansion trial of BNT329 (an anti-carbohydrate antigen 19-9 antibody-drug conjugate [CA19-9 ADC]) in patients with advanced solid tumors that express CA19-9.' (.

FCS旗下Sarah Cannon研究所药物开发单元主任是该研究的第一作者，该研究题为《BNT329（一种抗碳水化合物抗原19-9抗体药物偶联物[CA19-9 ADC]）在表达CA19-9的晚期实体瘤患者中的首次人体I/II期剂量递增和扩展试验》。

1076TiP)

1076TiP)

Judy Wang, MD

Judy Wang，医学博士

, associate director of drug development at FCS is first author of 'First-in-class Rac/Cdc42 inhibitor MBQ-167 in patients with metastatic breast cancer (MBC): safety and preliminary efficacy.'

FCS药物开发副总监是《首创Rac/Cdc42抑制剂MBQ-167在转移性乳腺癌（MBC）患者中的安全性和初步疗效》的第一作者。

(52P)

(52P)

FCS physicians are also co-authors of the following abstract poster presentations:

FCS 的医师也是以下摘要海报展示的共同作者：

Manish R. Patel, MD

马尼什·R·帕特尔，医学博士

Adjuvant intismeran autogene plus FOLFIRINOX in resectable pancreatic ductal adenocarcinoma: Results from a phase I study.

辅助性Intismeran Autogene联合FOLFIRINOX治疗可切除胰腺导管腺癌：一项I期研究的结果。

(3151P)

(3151P)

Manish R. Patel, MD and Cesar Perez, MD

马尼什·R·帕特尔医学博士和塞萨尔·佩雷斯医学博士

Phase 1 first-in-human (FIH) results of YL211, a c-Met targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors.

靶向c-Met的抗体药物偶联物（ADC）YL211在晚期实体瘤患者中的I期首次人体（FIH）研究结果。

(1017P)

(1017P)

Cesar Perez, MD

塞萨尔·佩雷斯，医学博士

Preliminary safety and pharmacokinetics of TJ101, an EGFR × B7-H3 bispecific antibody-drug conjugate, in patients with advanced solid tumors: Results from an ongoing global phase I study. (

TJ101（一种EGFR × B7-H3双特异性抗体药物偶联物）在晚期实体瘤患者中的初步安全性和药代动力学：一项正在进行的全球I期研究的结果。

1021P)

1021P)

Clinical and correlative outcomes of petosemtamab ± pembrolizumab (pembro) in recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC).

Petosemtamab ± 帕博利珠单抗（pembro）在复发/转移性头颈部鳞状细胞癌（r/m HNSCC）中的临床及相关结局。

(1594P)

(1594P)

IDE849, a delta-like ligand 3 (DLL3)-targeted topoisomerase I (TOPI) antibody–drug conjugate in advanced solid tumors.

IDE849，一种靶向delta样配体3（DLL3）的拓扑异构酶I（TOPI）抗体-药物偶联物，用于晚期实体瘤。

(1146eTiP)

(1146eTiP)

Judy S. Wang, MD

王朱迪，医学博士

Efficacy, safety, and biomarker analysis of DB-1310 (HER3-targeted ADC) in pretreated HR+/HER2- breast cancer: Updated global phase 1/2a trial.

DB-1310（靶向HER3的抗体偶联药物）在经治HR+/HER2-乳腺癌中的疗效、安全性及生物标志物分析：全球I/IIa期试验更新结果

(1846P)

(1846P)

A phase I trial of FAP-Exd (AVA6103), a fibroblast activation protein (FAP)-enabled pre|CISION® peptide-drug conjugate delivering sustained tumor microenvironment (TME) release of exatecan in patients with FAP-positive solid tumors

FAP-Exd（AVA6103）的I期临床试验：一种成纤维细胞活化蛋白（FAP）启用的pre|CISION®肽药物偶联物，在FAP阳性实体瘤患者中实现依喜替康在肿瘤微环境（TME）中的持续释放

(1134eTiP)

(1134eTiP)

An FCS physician is also a co-author of the following proffered paper presented at the podium:

一位FCS医师也是以下在讲台上展示的拟议论文的合著者：

Judy S. Wang, MD

王朱迪，医学博士

Safety and efficacy of JNJ-6143, a first-in-class oral AR-targeted regulated induced proximity targeting chimera at the optimal dose for further development in patients with mCRPC/mAPMR, including high-risk molecular features (2216O)

JNJ-6143（一种首创的口服雄激素受体靶向调节诱导邻近靶向嵌合体）在伴有高危分子特征的转移性去势抵抗性前列腺癌/转移性雄激素敏感性前列腺癌患者中用于进一步开发的最佳剂量的安全性和有效性（2216O）

As one of the nation's leading community oncology research programs, FCS continues to provide patients access to innovative clinical trials while helping bring the next generation of cancer treatments from the research setting to routine clinical practice. Through partnerships with

作为全国领先的社区肿瘤研究项目之一，FCS 持续为患者提供参与创新临床试验的机会，同时助力将新一代癌症治疗方案从研究环境转化为常规临床实践。通过与

Sarah Cannon Research Institute

莎拉·坎农研究所

(SCRI)—one of the world's leading oncology research organizations conducting community-based clinical trials—and Paradigm, Inc., FCS offers convenient access to clinical trials at nearly 30 locations statewide, including early-phase studies at Drug Development Units in Sarasota and Central Florida..

SCRI（全球领先的开展社区型临床试验的肿瘤研究机构之一）与 Paradigm, Inc. 合作，FCS 在全州近 30 个地点提供便捷的临床试验接入服务，其中包括在萨拉索塔和佛罗里达中部的药物研发单位开展的早期阶段研究。

All of the accepted abstracts will be published online at

所有已接受的摘要将在线发表于

ESMO

欧洲肿瘤内科学会

.

。

About Florida Cancer Specialists & Research Institute, LLC: (FLCancer.com)

关于佛罗里达癌症专家与研究所有限责任公司（FLCancer.com）

For more than 40 years, Florida Cancer Specialists & Research Institute (FCS) has embraced innovation to deliver world-class care and drive the dramatic transformation of oncology care through its robust clinical research program.

四十余年来，佛罗里达癌症专家与研究所（FCS）秉持创新精神，通过其强大的临床研究项目，提供世界级的医疗服务，并推动肿瘤护理领域的深刻变革。

FCS provides patients with access to a wide range of clinical trials, positioning it as a leader in research among private oncology practices in Florida and across the country. Through its robust clinical research program with Sarah Cannon Research Institute (SCRI) and a suite of independent site management programs, with advanced clinical trial matching technology, FCS offers patients innovative therapies close to home.

FCS 为患者提供参与广泛临床试验的机会，使其成为佛罗里达州乃至全美私人肿瘤诊疗机构中的研究领导者。通过与莎拉·坎农研究所（SCRI）开展的强大临床研究项目，以及一系列独立的站点管理项目和先进的临床试验匹配技术，FCS 让患者在家门口就能获得创新疗法。

Each year, FCS conducts more than 180 active clinical trials that directly elevate patient care and accelerate progress in oncology. Many of the cancer drugs approved by the FDA in the U.S over the past decade were accessible to patients at FCS through clinical trial participation before receiving approval..

每年，FCS 开展超过 180 项活跃的临床试验，直接提升患者护理水平并加速肿瘤学领域的进展。在过去十年中，美国食品药品监督管理局（FDA）批准的许多抗癌药物在获得批准之前，已通过临床试验参与的方式在 FCS 向患者提供。

Our outstanding team of highly trained and dedicated physicians is committed to delivering tailored treatment plans that make the best use of cutting-edge precision oncology advancements to enhance patient outcomes.

我们卓越的医疗团队由训练有素、敬业奉献的医师组成，致力于制定个性化治疗方案，充分利用前沿的精准肿瘤学进展，以改善患者预后。

SOURCE Florida Cancer Specialists & Research Institute

来源：佛罗里达癌症专家与研究所

21

二十一

%

%

more press release views with

更多新闻稿浏览量，通过

Request a Demo

申请演示